



Clinical Practice Recommendations for SRNS in children

A Scientific Workshop of the International Pediatric Nephrology Association

December 13-14, 2018

Irish College, Leuven, Belgium

WORKSHOP AGENDA

		LOCATION
<u>Wednesday, December 12</u>		
19:00	Dinner at Irish College (for those who already arrived and accepted invitation)	Restaurant
<u>Thursday, December 13</u>		
07:00	<i>BREAKFAST</i>	Restaurant
08:00	Welcome & Objectives of the Workshop <i>Dieter Haffner</i>	Conference Room 2
08:45	<u>Break-out Group Sessions</u>	
	• Group 1: How to evaluate a child for SRNS? <i>Marina Vivarelli</i>	Conference Room 2
	• Group 2: Which 1 st line (immunosuppressive) treatment are recommended? <i>Susan Samual</i>	Conference Room 3
	• Group 3: Which 2 nd line (immunosuppressive) treatment are recommended? <i>Franz Schaefer</i>	Green Room
10:45	<i>COFFEE BREAK</i>	
11:00	Plenary session: Reports and Discussion on Breakout Groups 1-3, Next steps	Conference Room 2
13:00	<i>LUNCH</i>	
14:00	<u>Break-out Group Sessions</u>	
	• Group 4: Which other measures should be undertaken? <i>Dieter Haffner</i>	Conference Room 2
	• Group 5: How to monitor & treat complications/side effects? <i>Agnes Trautmann</i>	Conference Room 3
	• Group 6: How to detect, prevent & treat relapsing SRNS in native kidneys? <i>Hong XU</i>	Green Room
16:00	<i>Coffee break</i>	
16:30	Plenary session: Reports and discussion on Breakout Groups 4-6, Next steps	Conference Room 2
18:30	End of day one	



19:00 *GROUP DINNER*

Restaurant

Friday, December 14^h

07:00 *BREAKFAST*

Restaurant

08:00 Plan of the day *Dieter Haffner*

Conference Room 2

08:15 Break-out Group Sessions

- Group 7: How to manage patients with ESKD?

Management of transplantation & recurrence after transplantation *Debbie Gipson*

Conference Room 2

- Group 8: Are there any ethical issues? *Adita Sinha*

Conference Room 3

- Group 9: How to adapt CPR in under-resourced environments or populations? *Francisco Cano*

Green Room

10:15 *COFFEE BREAK*

10:30 Plenary session: Reports and discussion on Breakout Groups 7-9, Next steps

Conference Room 2

12:30 Future clinical and research goals

Conference Room 2

13:00 Publication plan & Closing remarks

Conference Room 2

13:15 *LUNCH*



List of Attendees: Core group members

Name (n = 21)	Regional Society	City, country	Speciality/function	Email address
Dieter Haffner	ESPN	Hannover, Germany	Ped. Nephrology / coordinator	Haffner.dieter@mh-hannover.de
Agnes Trautmann		Heidelberg, Germany	Epidemiology / ped. nephrology	Agnes.Trautmann@med.uni-heidelberg.de
Luciana Feltran	ALANEPE	Sao Paulo, Brasil	Ped. Nephrology	glfeltran@uol.com.br luciana.feltran@gmail.com
Francisco Cano	ALANEPE	Santiago, Chile	Ped. Nephrology	fcanosch@gmail.com
Elisabeth Hodson	ANZPNA	Sydney, Australia	Ped. Nephrology & epidemiology	emhodson@exemail.com.au elisabeth.hodson@health.nsw.gov.au
Olivia Boyer	ESPN	Paris, France	Ped. Nephrology & genetics	olivia.boyer@aphp.fr
Franz Schaefer	ESPN	Heidelberg, Germany	Ped. Nephrology	Franz.Schaefer@med.uni-heidelberg.de
Marina Vivarelli	ESPN	Rome, Italy	Ped. Nephrology	marina.vivarelli@OPBG.net
Moin Saleem	ESPN	Bristol, UK	Ped. Nephrology & genetics	m.saleem@bristol.ac.uk
Ng Kar Hui	ASPNA	Singapore, Singapore	Ped. Nephrology	paenkh@nus.edu.sg
Aditi Sinha	ASPNA	New Dehli, India	Ped. Nephrology	aditishaaaiims@gmail.com
Hong Xu	ASPNA	Shanghai, China	Ped. Nephrology	hxu@shmu.edu.cn
Yam Ngo Lim	ASPNA	Kuala Lumpur, Malaysia	Ped. Nephrology	Ynlim57@gmail.com
William Smoyer	ASPN	Columbus, USA	Ped. Nephrology	William.Smoyer@nationwidechildrens.org
Debbie Gipson	ASPN	Ann Arbor, USA	Ped. Nephrology & genetics	dgipson@umich.edu
Susan Samuel	CAPN	Calgary, Canada	Ped. Nephrology	Susan.Samuel@albertahealthservices.ca
Neveen Soliman	AFPNA	Cairo, Egypt	Ped. Nephrology	neveen.soliman@gmail.com
Ifeoma Anochie	AFPNA	Port Harcourt, Nigeria	Ped. Nephrology	anochieify@hotmail.com
Koichi Nakanishi	JSPN	Okinawa, Japan	Ped. Nephrology	knakanis@med.u-ryukyu.ac.jp
Janina Müller-Seile	-	Erlangen, Germany	Adult Nephrology & Transition	janina.mueller-deile@uk-erlangen.de
Jan Ulrich Becker	-	Cologne, Germany	Nephropathology	jan.becker@uk-koeln.de



Breakout sessions groups (the ones written in bold letters are coordinating the specific PICO questions)






Group									
1How to evaluate..	Marina Vivarelli	William Smoyer	Koichi Nakanishi	Ng Kar Hui	Ifeoma Anochie	Moin Saleem	Luciana Feltran	Jan Ulrich Becker	Aditi Sinha
2 1 st line Tx	Susan Samuel	Elisabeth Hodson	Moin Saleem	Ng Kar Hui	Olivia Boyer	Becker	Francisco Cano	William Smoyer	Franz Schafer Dieter Haffner
3 2 nd line Tx	Franz Schaefer	Elisabeth Hodson	Moin Saleem	Ng Kar Hui	Marina Vivarelli	William Smoyer	Deb Gipson	Aditi Sinha	Agnes & Janina
4 other measures	Dieter Haffner	Susan Samuel	Franz Schaefer	Neveen Soliman	Janina Müller-Seile				
5 monitoring& complications	Agnes Trautmann	YN Lim	Olivia Boyer	Susan Samuel	Hong XU	Debie Gipson			
6 SRNS relapse	Hong XU	Olivia Boyer	Koichi Nakanishi	Janina Müller-Seile	Aditi Sinha	Marina Vivarelli			
7 ESKD, KTX, recurrence	Debbie Gipson	Luciana Feltran	Olivia Boyer	Jan Ulrich Becker	Hong XU	Ng Kar Hui	Janina Müller-Seile		
8 ethical issues	Aditi Sinha	Debie Gipson	Dieter Haffner	Neveen Soliman	Agnes Trautmann				
9 under-resourced enviroments	Francisco Cano	Yam Ngo Lim	Ifeoma Anochie	Jan Ulrich Becker	Luciana Feltran	Susan Samuel	Aditi Sinha	Neveen Soliman	

Morning of December 13: Groups 1, 2, and 3; Afternoon of December 13: Groups 4, 5, and 5

Morning of December 14: Groups 7, 8, and 9



Grading system of the American Academy of Pediatrics

Aggregate Evidence Quality	Benefit or Harm Predominates	Benefit and Harm Balanced
Level A Intervention: Well-designed and conducted trials, meta-analyses on applicable populations Diagnosis: Independent gold standard studies of applicable populations	 <p>Strong Recommendation</p>	 <p>Weak Recommendation (based on balance of benefit and harm)</p>
Level B Trials or diagnostic studies with minor limitations; consistent findings from multiple observational studies	 <p>Moderate Recommendation</p>	
Level C Single or few observational studies or multiple studies with inconsistent findings or major limitations.	 <p>Weak Recommendation (based on low quality evidence)</p>	
Level D Expert opinion, case reports, reasoning from first principles		<p>No recommendation may be made</p>
Level X Exceptional situations where validating studies cannot be performed and benefit or harm clearly predominates	 <p>Moderate Recommendation</p>	